Study of Secukinumab Treatment for Moderate-to-Severe Hidradenitis Suppurativa in Canadian Adults

What this Trial Is About

This research aims to assess treatment outcomes and patterns, as well as the safety of secukinumab, in Canadian patients diagnosed with moderate-to-severe hidradenitis suppurativa HS in routine clinical practice. It focuses on describing the baseline characteristics of these patients and evaluating real-world use of secukinumab. Participants are patients newly prescribed secukinumab as part of their usual care. The study follows these patients over time to observe changes in disease severity and treatment adjustments, including dose changes from every 4 weeks to every 2 weeks or vice versa over a 12-month period. Throughout the study, participants undergo assessments at baseline and months 3, 6, and 12. These evaluations include measuring disease severity using the International HS Severity Score System, abscess and nodule count, clinical response rates, and monitoring adverse events and treatment discontinuation. Researchers also collect demographic and clinical data to understand treatment effects and safety in a real-world setting.

Real-world Secukinumab Outcomes in Canadian HS Patients